$6.95 0.3%
RXRX Stock Price vs. AI Score
Data gathered: November 8

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.


Recursion Pharmaceuticals
Price $6.95
Target Price Sign up
Volume 2,300,000
Market Cap $2.03B
Year Range $5.92 - $12.81
Dividend Yield 0%
Analyst Rating 29% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2426M55M-29M-96M-93M-0.340
Q2 '2414M46M-32M-98M-96M-0.400
Q1 '2414M46M-32M-91M-89M-0.390
Q4 '2311M45M-34M-93M-94M-0.420
Q3 '2311M43M-33M-93M-90M-0.430

Insider Transactions View All

Marriott Tina filed to sell 521,138 shares at $6.3.
October 28 '24
Borgeson Blake filed to sell 7,089,007 shares at $6.7.
October 17 '24
Secora Michael filed to sell 1,450,881 shares at $6.4.
October 10 '24
Gibson Christopher filed to sell 762,656 shares at $6.1.
October 4 '24
Borgeson Blake filed to sell 7,098,428 shares at $6.2.
October 3 '24

What is the Market Cap of Recursion Pharmaceuticals?

The Market Cap of Recursion Pharmaceuticals is $2.03B.

What is the current stock price of Recursion Pharmaceuticals?

Currently, the price of one share of Recursion Pharmaceuticals stock is $6.95.

How can I analyze the RXRX stock price chart for investment decisions?

The RXRX stock price chart above provides a comprehensive visual representation of Recursion Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Recursion Pharmaceuticals shares. Our platform offers an up-to-date RXRX stock price chart, along with technical data analysis and alternative data insights.

Does RXRX offer dividends to its shareholders?

As of our latest update, Recursion Pharmaceuticals (RXRX) does not offer dividends to its shareholders. Investors interested in Recursion Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Recursion Pharmaceuticals?

Some of the similar stocks of Recursion Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.